Evidence map›Paper›PMID 23480167›Full record

ArticleJournal of the American Chemical Society2013

Forming cross-linked peptidoglycan from synthetic gram-negative Lipid II.

Matthew D Lebar, Tania J Lupoli, Hirokazu Tsukamoto, Janine M May, Suzanne Walker, Daniel Kahne

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 57 citations in OpenAlex.

  1. Lipid II unlocked: strategies for obtaining a major antibiotic target.Chemical communications (Cambridge, England) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Membrane Potential Is Required for MurJ Function.Journal of the American Chemical Society · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Antimicrobial lipopeptide tridecaptin A1 selectively binds to Gram-negative lipid II.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew D LebarDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Tania J Lupoli
Hirokazu Tsukamoto
Janine M May
Suzanne Walker
Daniel Kahne
Harvard University · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RIDER, TODD H. · 2003 to 2013
$113.7M
Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI Michael S Gilmore · 2009 to 2026
$39.4M
Studies Toward Hybrid Glycopeptide AntibioticsR01GM066174 · NIGMS · PRINCETON UNIVERSITY · PI KAHNE, DANIEL · 2002 to 2018
$8.9M
Mechanism and Inhibition of Enzymes that Assemble Bacterial Cell WallR01GM076710 · NIGMS · HARVARD MEDICAL SCHOOL · PI WALKER, SUZANNE · 2007 to 2019
$5.9M
Mechanistic studies on peptidoglycan tailoring that mediate biofilm stabilityF32GM103056 · NIGMS · HARVARD UNIVERSITY · PI LEBAR, MATTHEW DENNIS · 2012 to 2013
$101k
NIAID NIH HHS AI057159NIAID NIH HHS P01 AI083214NIAID NIH HHS U54 AI057159NIGMS NIH HHS F32 GM103056NIGMS NIH HHS R01 GM066174NIGMS NIH HHS R01 GM076710NIGMS NIH HHS R01 GM76710
6 · The paper itself

Abstract

The bacterial cell wall precursor, Lipid II, has a highly conserved structure among different organisms except for differences in the amino acid sequence of the peptide side chain. Here, we report an efficient and flexible synthesis of the canonical Lipid II precursor required for the assembly of Gram-negative peptidoglycan (PG). We use a rapid LC/MS assay to analyze PG glycosyltransfer (PGT) and transpeptidase (TP) activities of Escherichia coli penicillin binding proteins PBP1A and PBP1B and show that the native m-DAP residue in the peptide side chain of Lipid II is required in order for TP-catalyzed peptide cross-linking to occur in vitro. Comparison of PG produced from synthetic canonical E. coli Lipid II with PG isolated from E. coli cells demonstrates that we can produce PG in vitro that resembles native structure. This work provides the tools necessary for reconstituting cell wall synthesis, an essential cellular process and major antibiotic target, in a purified system.

Indexed as

Escherichia coliEscherichia coli ProteinsPenicillin-Binding ProteinsPeptidoglycanPeptidoglycan GlycosyltransferaseSerine-Type D-Ala-D-Ala CarboxypeptidaseUridine Diphosphate N-Acetylmuramic AcidEscherichia coli Proteinsmuramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenolpenicillin-binding protein 1A, E colipenicillin-binding protein 1B, E coliPenicillin-Binding ProteinsPeptidoglycanPeptidoglycan GlycosyltransferaseSerine-Type D-Ala-D-Ala CarboxypeptidaseUridine Diphosphate N-Acetylmuramic Acid

Identifiers

PMID23480167
PMCPMC3658469
OpenAlexW2016891160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.